Rationale: Isoniazid-monoresistant tuberculosis (INH-monoresistant TB) is the most common drug-resistant TB type in the United States; however, its impact on TB treatment outcomes is not clear.
Tuberculosis (TB) is a major global health problem with 10.4 million incident cases and 1.4 million deaths among HIV-negative cases annually (1) . In 2016 the World Health Organization (WHO) reported 580,000 cases of rifampin-resistant (including multidrugresistant [MDR] ) TB (1) . Nearly 10% of TB cases are isoniazid resistant (i.e., TB strains resistant to isoniazid without rifampin resistance) (2) (3) (4) , and the global burden of drug-resistant TB (DRTB) will likely reach 1 million incident cases annually. Global TB control is severely inhibited by DRTB, which requires substantial resources to diagnose and treat (5) . In 2015, 11% of patients in the United States with TB were resistant to at least isoniazid (including MDR TB) (6) . During 2009-2014, the state of Georgia reported an average of two MDR TB cases annually, but the rate of isoniazid resistance (INH-R) ranged from 7 to 22% (7) . Isoniazid (INH)-monoresistant TB (i.e., TB strains resistant to INH only) is the most common type of drug-resistant TB among those with monoresistant TB (8) , but evidence about whether INH-monoresistant TB is associated with clinical characteristics and immunosuppressive comorbidities or impacts TB treatment outcomes is limited.
Previous studies reported associations between INH-monoresistant TB and smoking (9) , history of incarceration (10, 11) , positive tuberculin skin test result (10) , foreign-born status (12) , drug use (13) , and previous TB treatment (for active and latent TB) (12) . Other studies reported that patients with INH-monoresistant TB have similar clinical presentation (i.e., presence of radiographic cavities) compared with patients with drug-susceptible TB (14) . But the majority of these previous studies were conducted with macrolevel data (i.e., Israel, United States, and India), and little is known about clinical characteristics of patients in local settings with INHmonoresistant TB. Among patients in Georgia with TB, the prevalence of immunosuppressive conditions is high (6) , but the distribution of characteristics among patients with INH-monoresistant TB is unknown. Identifying subgroup populations in which INH-monoresistant TB is prevalent is critical to monitor epidemiologic trends in TB transmission and may inform TB prevention strategies.
The 2016 WHO guidelines for treatment of DRTB highlight the need for additional evidence regarding the impact of INH resistance on TB treatment outcomes (15) . Drug resistance that is not MDR TB may increase the risk of poor TB treatment outcomes (10, 16) such as treatment failure (2, 17) , TB relapse (2), acquisition of additional resistance (17) , and subsequent development of acquired MDR TB (2, 18, 19) . A study conducted among a cohort of patients with tuberculous meningitis also reported that a higher proportion of patients with INH resistance died during treatment when compared with those without (20) . Two meta-analyses reported that patients with INH-R treated according to standard TB regimens had increased risk of poor outcomes (21, 22) , but these meta-analyses did not assess the effect of INH-R on culture conversion. Another previous study reported similar TB treatment success rates among patients with and without INH monoresistance (12) . Using data from the state of Georgia, our study aimed to 1) determine patient characteristics associated with INH-monoresistant TB and 2) estimate the relationship between INH monoresistance and response to TB treatment (including rate of sputum culture conversion, final treatment outcome, and mortality).
Methods

Setting and Design
We performed a retrospective cohort study of TB cases in Georgia during [2009] [2010] [2011] [2012] [2013] [2014] . In Georgia, all TB cases are reported to the Georgia Department of Public Health (GDPH) at the county or state level (23 (24) .
Study information was collected from the SENDSS. Based on the U.S. Centers for Disease Control and Prevention (CDC)'s Report of Verified Case of Tuberculosis (RVCT), the SENDSS routinely collects medical record and laboratory information on patients with TB including demographics and clinical information. DST results for INH, RIF, and EMB were performed by the GDPH, using mycobacterial growth indicator tubes (BACTEC, BD Dickinson) as previously described (25) . If resistance to any first-line TB drugs was detected, samples were sent to the CDC for second-line DST (26) .
Definitions
Primary outcomes in this study were 1) INH monoresistance at time of TB diagnosis, 2) rate of sputum culture conversion, and 3) TB treatment outcomes (final treatment outcome and mortality). First, INH monoresistance was defined for strains of Mycobacterium tuberculosis (MTB) resistant to INH only with recorded DST results available for at least both INH and RIF. Patients were classified as having drugsusceptible TB if they were susceptible to at least INH and RIF and had no reported resistance to other drugs (PZA and EMB). Other types of drug resistance (non-INHmonoresistant TB, polydrug-resistant TB [i.e., resistance to two or more TB drugs but not MDR TB], and MDR TB) were excluded. Second, time to sputum culture conversion was defined as the time (in days) from TB treatment initiation to date of the first of two consecutively negative sputum cultures reported to the SENDSS. Third, final TB treatment outcome was defined as favorable or poor. Patients who were cured or completed TB treatment were categorized as having a favorable outcome (27) . Patients with TB who died during treatment, were lost to follow-up, or stopped/refused TB treatment were categorized as having a poor outcome (28) . We also examined all-cause mortality during TB treatment separately.
Other patient characteristics used in the study included demographic information, prior TB history, illicit drug use, alcohol abuse, history of latent TB infection prophylaxis, acid-fast bacilli smear status, cavitary disease, and site of disease. HIV and diabetes were defined by the SENDSS. Age was categorized according to standard WHO classifications (1) . We used GDPH categories for race/ethnicity, which included nonHispanic white, non-Hispanic black, Hispanic all races, and non-Hispanic Asian. Treatment duration was defined as number of days between TB treatment initiation and treatment completion and classified into three categories: "<6 months," "7-12 months," and ">12 months."
Spoligotyping and mycobacterial interspersed repetitive unit analysis were used to identify TB genotypes and were ORIGINAL RESEARCH categorized dichotomously according to the largest Georgia MTB cluster, classified as "GENType G05625" and "other" (7). GENType G05625 was associated with a recent TB outbreak among homeless shelter residents in the Atlanta area (7).
Statistical Analyses
We used x 2 and Fisher exact tests to assess bivariate associations between characteristics of patients and prevalent INH monoresistance. Multivariable logistic regression was used to determine the adjusted association between patient characteristics and INH monoresistance. We used cumulative incidence curves and cause-specific proportional hazard models to evaluate whether INH-monoresistant TB was associated with rate of culture conversion in the presence of a competing risk (i.e., all-cause mortality during TB treatment). Patients with TB were censored if they were lost to follow-up, stopped/ refused TB treatment (with no prior documentation of culture conversion), or did not convert sputum cultures to negative by time of treatment completion. Proportional hazard assumptions were assessed by three methods: 1) graphically, 2) goodness-of-fit tests, and 3) timedependent models (29 
ORIGINAL RESEARCH
assessed by likelihood ratio test. Sensitivity analyses were used to assess model misspecification by fitting multiple covariate subsets, including logistic models with GENType G05625 information to determine the adjusted association between HIV and INH-monoresistant TB. An additional sensitivity analysis was performed to assess error from unmeasured confounding due to treatment regimen change in estimating associations between INH monoresistance and TB treatment outcomes (31) . Analyses were performed with SAS version 9.4 (SAS Institute), with a two-sided P value less than 0.05 considered significant.
Institutional Review Board
This study was reviewed and approved by the institutional review boards (IRBs) at Georgia State University, Emory University, and the GDPH (Atlanta, GA). All IRBs granted a waiver of informed consent for the use of TB surveillance data.
Results
Baseline (Figure 3) .
In multivariable proportional hazard analyses, we found similar rates of culture Definition of abbreviations: aOR = adjusted odd ratio; CI = confidence interval; cOR = crude odds ratio; CXR = chest X-ray; LTBI = latent TB infection; NA = not available; TB = tuberculosis; TST = tuberculin skin test. *Adjusted odds ratio after controlling for age, sex, race, foreign born, occupation, homelessness, TB history, illicit drug use, HIV status, diabetes, cavitary disease, and miliary disease (N = 1,141). †
The finding is statistically significant at level of confidence of 5% (P , 0.05). Table 3 . Univariate and multivariable odds and hazard rate ratio analyses for TB treatment outcomes among patients in the state of Georgia with culture-confirmed TB Crude hazard ratio for sputum culture conversion from the conventional Cox proportional hazard model. x Cause-specific Cox proportional hazard model accounting for death as a competing risk. Model was adjusted for age, sex, HIV status, diabetes status, tuberculin skin test at baseline, and smear status. jj Included in poor TB treatment outcomes were patients who died during TB treatment, were lost to follow-up, or who stopped/refused TB treatment. ¶ Odds ratios were estimated from the logistic regression model. **Model adjusted for age, sex, HIV status, smear, and TB treatment duration.
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In the United States more than 1 in 10 patients with TB had INH resistance in 2014 (6); however, few studies have reported the clinical characteristics of patients with INH-monoresistant TB (10, 12) . A previous study of a nationwide cohort of patients with TB, conducted from 1993 to 2003 in the United States, reported that the odds of INH-monoresistant TB were similar among patients with HIV infection compared with patients who were HIV negative (aOR, 1.0; 95% CI, 0.9-1.1) (10) . A retrospective study of a cohort from San Francisco reported a lower proportion of INH monoresistance among TB patients with HIV infection compared with those who were HIV negative (aOR, 0.5; 95% CI, 0.2-1.2) (12). Unlike these two previous studies, our findings suggest that TB patients with HIV infection had almost twice the odds of INH-monoresistant TB compared with HIV-negative subjects. The association between HIV status and INHmonoresistant TB we reported is likely due to the clustering of patients with HIV infection in the setting where an INHmonoresistant TB strain is actively circulating (32) . In 2014, the GDPH reported a large TB genotype cluster that was 100% resistant to INH (including 27 patients from the recent homeless shelter outbreak in Fulton County), of which 41% had HIV infection (7) . Our findings suggest a relationship between HIV infection with this recent TB outbreak among the homeless population in metropolitan Atlanta, indirectly leading to the observed association between HIV infection and INH-monoresistant TB. After accounting for the clustering of the outbreak genotype, we do not believe that HIV is an independent risk factor for increased risk of INH-monoresistant TB.
Time to sputum culture conversion is an established metric for clinical management of patients with TB, is approved by the U.S. Food and Drug Administration (FDA) as an endpoint for phase 2 trials for TB drugs (33) , and is a predictor of final TB treatment outcome (34) correlated with regimen effectiveness (35) . However, there are limited data on the relationship between INH monoresistance and time required to achieve sputum culture conversion (12, 16) . Our findings indicated that patients with INHmonoresistant TB had a similar rate of sputum culture conversion compared with patients with drug-susceptible TB; therefore, altered treatment might not be required in similar clinical settings. Similar to our finding, a study of a smaller cohort from Atlanta also reported that INHmonoresistant TB was not associated with time to sputum culture conversion (36) . Similar to a retrospective cohort study conducted among children at three hospitals in the Western Cape, South Africa (37), we also found that INHmonoresistant TB was not significantly associated with either poor treatment outcome or all-cause mortality during TB treatment. Our findings contrast with a retrospective longitudinal study conducted in South Africa and reporting that INHmonoresistant TB was associated with increased risk of treatment failure (aOR, 6.84; 95% CI, 4.29-10.89) and mortality during TB treatment (aOR, 1.81; 95% CI, 1.11-2.95) (38 (39) . However, unlike our study, the studies from South Africa and Mexico did not adjust for baseline smear status or duration of TB treatment, and both had a higher proportion of patients with previous TB treatment (60 and 10%, respectively). In general, our findings contrast with a metaanalysis reporting that current WHO treatment guidelines might be insufficient to treat patients with INH-R, demonstrated by a significantly higher cumulative incidence of failure and relapse combined among INH-R compared with drugsusceptible patients (21) . However, unlike ORIGINAL RESEARCH most previous studies, we specifically studied patients with INH-monoresistant TB in a population with infrequent TB retreatment; we thoroughly evaluated confounder adjustment methods with sensitivity analyses; and our primary outcomes included rate of sputum culture conversion, poor TB treatment outcome, and all-cause mortality.
INH has high early bactericidal activity (EBA) (40, 41) , defined as the ability to reduce MTB concentration during the early phase of TB treatment (42) . In our study, the similarity of culture conversion and TB treatment outcomes between patients with INH-monoresistant and drug-susceptible TB suggests that despite INH monoresistance, some bactericidal activity likely remains. This finding is supported by an EBA study conducted in Cape Town, reporting that patients with INH resistance still had positive EBAs (ranging from 0.005 to 0.09 log 10 cfu/ml sputum/d) (43) .
Our study was subject to limitations. First, our study only included a cohort of patients with TB who had a positive culture result at baseline and available DST results. DST was not performed uniformly among patients; some patients did not have DST results for EMB and PZA. Therefore, the generalizability of our findings to clinically defined (culture-negative) patients with TB may be limited. However, we performed additional analyses (data not shown) categorizing those with pending/missing diagnostic culture results as cultureconfirmed; these analyses resulted in no substantial differences in the adjusted HR for culture conversion (aHR, 1.25 vs. 1.27) when comparing patients with INH-monoresistant TB with those with drug-susceptible TB. Furthermore, patients with culture-confirmed and clinical TB in our study were similar with respect to birthplace, occupation, HIV status, and diabetes status. Second, our study used surveillance data only, and did not include information on contact tracing to analyze epidemiologic links for the INHmonoresistant TB transmission in Georgia. We also did not have information on the level of INH resistance (i.e., high-vs. lowlevel resistance) among patients with INHmonoresistant TB. However, 41.3% of patients with INH-monoresistant TB in our study were from Fulton County, where a recent TB outbreak occurred, suggesting that the observed relationship was more likely to be associated with TB clustering. Third, we did not have direct measures of the extent of immunosuppression among patients with HIV or diabetes. For example, we did not have CD4 count or viral load information on patients with HIV infection. We also did not have a measure of blood glucose control among patients with TB and diabetes. In addition, as we relied on surveillance records, some misclassification of HIV status, diabetes status, and illicit drug and alcohol use was possible. Nonetheless, previous studies have demonstrated that TB notification and surveillance systems in the United States, similar to the one used in these analyses, have high accuracy and reliability rates (44) . Fourth, we did not have information on treatment regimen change or adherence during TB treatment for patients in the cohort. However, patients in Georgia are treated according to U.S.
CDC guidelines, and the TB treatment regimens for each type of TB likely included little variation (36, 45) . Moreover, our sensitivity analysis for unmeasured confounding by treatment regimen change suggested this error may be away from the null. Despite limitations, the present study included a large and well-characterized cohort of patients with culture-confirmed TB. Our study also had a high coverage of genotyping among patients with culture-positive TB.
Conclusions
Our evaluation of the impact of INH monoresistance on three clinical metrics of response to TB treatment did not find evidence to suggest that patients with INH-monoresistant TB required altered treatment considerations. Patients with and without INH-monoresistant TB had similar sputum culture conversion rates, final TB treatment outcomes, and mortality risk. This study adds important information regarding the association between clinical epidemiologic factors and INHmonoresistant TB. The association between HIV status, homelessness, and INHmonoresistant TB reported in our study may mirror the recent TB outbreak among the homeless population in the Atlanta metropolitan area. Expanding our current understanding of the relationship between INH-monoresistant TB and response to TB treatment is needed to inform TB treatment guidelines. n
